Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype by Deligny, C, Murdamoothoo, D, Gammage, A, Gschwandtner, M, Gschwandtner, M, Midwood, K, Midwood, K

More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis by Gschwandtner, M, Derler, R, Midwood, K

Interfering with the CCL2-glycosaminoglycan axis as a potential approach to modulate neuroinflammation by Gschwandtner, M, Piccinini, A, Gerlza, T, Adage, T, Kungl, A

Investigating chemokine-matrix networks in breast cancer: tenascin-C sets the tone for CCL2 by Gschwandtner, M, Gammage, A, Deligne, C, Mies, L, Schwenzer, A, Midwood, KIM

Eruptive epidermoidzysten nach imiquimod-therapie eines rezidivierenden basalzellkarzinoms by Woltsche, N, El-Shabrawi-Caelen, L, Deinlein, T, Kupsa, R, Gschwandtner, M, Hofmann-Wellenhof, R, Zalaudek, I

Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo by Gschwandtner, M, Strutzmann, E, Teixeira, M, Anders, H, Diedrichs-Möhring, M, Gerlza, T, Wildner, G, Russo, R, Adage, T, Kungl, A

Structural fuzziness of the RNA-organizing protein SERF determines a toxic gain-of-interaction by Meyer, N, Dellago, H, Tam-Amersdorfer, C, Merle, D, Parlato, R, Gesslbauer, B, Almer, J, Gschwandtner, M, Leon, A, Franzmann, T, Grillari, J, Kungl, A, Zangger, K, Falsone, S